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Escape from the extremely stressful opiate with-
drawal syndrome may motivate opiate seeking
and taking. The corticotropin-releasing factor
receptor-1 (CRF1) pathway mediates behavioral
and endocrine responses to stress. Here, we re-
port that genetic inactivation (CRF1
/) as well
as pharmacological antagonism of the CRF/
CRF1 receptor pathway increased and pro-
longed the somatic expression of opiate with-
drawal. Opiate-withdrawn CRF1
/ mice also
showed aberrant CRF and dynorphin expres-
sion in the paraventricular nucleus of the hypo-
thalamus (PVN) and the striatum, indicating pro-
found impairments in stress-responsive brain
circuitry. Intake of nonstressful amounts of cor-
ticosterone effectively reduced the exaggerated
somatic reactions of CRF1
/ mice to opiate
withdrawal. Exogenous corticosterone also re-
stored ‘‘wild-type-like’’ patterns of CRF and
dynorphin gene expression in the PVN and the
striatum of opiate-withdrawn CRF1
/ mice, re-
spectively. The present findings unravel a key
role for the hypothalamus-pituitary-adrenal
(HPA) system and brain extra-hypothalamic
CRF/CRF1 receptor circuitry in somatic, molec-
ular, and endocrine alterations induced by opi-
ate withdrawal.
INTRODUCTION
Opiate dependence is a major public health issue whose
incidence rate may dramatically increase in the next years.
Recent reports show an alarming raise in the recreational
use of heroin and other opiate drugs among adolescents
(NIDA, 2005). In opiate-dependent individuals, heroin
‘‘highs’’ are inexorably followed by a severe opiate with-Ndrawal syndrome comprised of somatic signs and symp-
toms and negative affective states (O’Brien, 1996). Be-
sides a positive reinforcement theory of drug addiction
(Shaham et al., 2003), studies indicate that escape from
the extremely aversive and stressful opiate withdrawal
syndrome may motivate heroin-seeking and -taking be-
haviors (Carrera et al., 1999; Kenny et al., 2006; Lu et al.,
2005; Schulteis and Koob, 1996). However, current treat-
ments do not effectively relieve the opiate withdrawal
syndrome, thus leaving opiate-dependent individuals
vulnerable to relapse to drug intake.
The corticotropin-releasing factor (CRF) system is a
major coordinator of behavioral and endocrine responses
to stress (Heinrichs et al., 1994; Rivier and Vale, 1983). The
CRF system might also mediate the motivational effects of
drug dependence. Functional antagonism of CRF neuro-
transmission reduces stress-induced reinstatement of
drug-seeking behavior and ameliorates negative affec-
tive-like states associated with alcohol, cocaine, or opiate
withdrawal (Heinrichs et al., 1995; Sarnyai et al., 1995;
Shaham et al., 1998; Stinus et al., 2005; Valdez et al.,
2002). The studies cited above suggest new therapeutic
strategies for opiate dependence.
In mammals, CRF actions are mediated by two distinct
receptor pathways, termed CRF1 and CRF2 (Hauger et al.,
2003). Genetically engineered mouse models have al-
lowed the observation of distinct, and often opposite,
functions for the two known CRF receptor pathways in
HPA axis and affective-like behavioral responses to
stressors (Bale and Vale, 2004; Contarino and Gold, 2002).
In particular, studies with CRF1 receptor-deficient mice
have revealed that the CRF/CRF1 receptor pathway medi-
ates HPA axis functions and behavioral strategies essen-
tial to cope with stressful events (Contarino et al., 1999;
Smith et al., 1998; Timpl et al., 1998). Moreover, using
CRF1 receptor-deficient mice, we have recently found
that disruption of the CRF/CRF1 receptor pathway elimi-
nates the negative affective states of opiate withdrawal
(Contarino and Papaleo, 2005). However, the involvement
of the stress-responsive HPA system and brain extrahy-
pothalamic CRF/CRF1 receptor circuitry in behavioral,euron 53, 577–589, February 15, 2007 ª2007 Elsevier Inc. 577
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somatic opiate withdrawal remains largely unknown.
To elucidate the role for the CRF/CRF1 receptor path-
way in somatic components of the opiate withdrawal syn-
drome, here we used CRF1 receptor-deficient (CRF1
+/
and CRF1
/) mice and the CRF1 receptor-preferring
antagonist antalarmin (Smith et al., 1998; Wong et al.,
1999). In keeping with the clinical setting, where signs
and symptoms of opiate withdrawal ‘‘spontaneously’’ and
gradually rise along with the drug removal from the body
(O’Brien, 1996), our studies were conducted in mice un-
dergoing spontaneous opiate withdrawal. Active heroin-
dependent individuals have reduced plasma levels of cor-
ticotropin (ACTH) and cortisol, flattened circadian rhythms
of cortisol, and blunted HPA axis responses to stressors
(Facchinetti et al., 1985; Kreek and Koob, 1998); however,
the physiopathological role for these alterations in somatic
components of the opiate withdrawal syndrome remains
largely unknown. CRF1
/ mice also display flattened cir-
cadian rhythms of corticosterone, the main glucocorticoid
hormone in rodents, and deficient ACTH and corticoste-
rone responses to stressors (Smith et al., 1998; Timpl
et al., 1998). Thus, to examine the specific contribution
of impaired HPA axis functions to opiate withdrawal, we
treated CRF1
/ mice with nonstressful amounts of corti-
costerone. Moreover, the use of antalarmin allowed us to
investigate the HPA axis-independent role for the CRF/
CRF1 receptor pathway in opiate withdrawal. Antalarmin
attenuates behavioral responses to stress but does not af-
fect basal or stress-related activity of the HPA axis (Deak
et al., 1999; Jutkiewicz et al., 2005; Wong et al., 1999;
Zorrilla et al., 2002). Furthermore, we examined the spe-
cific role for impaired HPA axis functions associated with
the CRF1 receptor deficiency upon opiate withdrawal-
induced expression of CRF and the opioid peptide dynor-
phin in the PVN and the striatum, brain regions integrating
behavioral, endocrine, and autonomic responses to stress
(Koob and Heinrichs, 1999; Reyes et al., 2005). PVN CRF
drives basal and stress-related activity of the HPA axis
(Sawchenko et al., 1993); also, hypothalamic dynorphin
and CRF circuitry are activated during the stress of opiate
withdrawal (Houshyar et al., 2004; Lightman and Young,
1988; Rattan et al., 1992). Moreover, recent evidence indi-
cates a role for striatal dynorphin circuitry in somatic com-
ponents of the opiate withdrawal syndrome (Zachariou
et al., 2006).
The present study reveals a fundamental role for the
HPA system and brain extrahypothalamic CRF/CRF1 re-
ceptor circuitry in somatic, gene expression, and endo-
crine changes associated with the stressful condition of
opiate withdrawal.
RESULTS
Increased Somatic Opiate Withdrawal
in CRF1
/ Mice
To induce opiate dependence, wild-type, CRF1
+/, and
CRF1
/ mice were repeatedly treated with escalating578 Neuron 53, 577–589, February 15, 2007 ª2007 Elsevier Incmorphine doses. Unlike constant morphine infusions or
pellets, intermittent treatment with escalating morphine
doses closely parallels the drug intake pattern of opiate-
dependent humans. Also, in rodents termination of inter-
mittent morphine treatment is followed by HPA axis alter-
ations that are similar to those seen in opiate-withdrawn
humans (Houshyar et al., 2004). CRF1 receptor deficiency
did not affect body weight (BW) loss induced by intermit-
tent morphine administration (see Figure S1 in the Supple-
mental Data available with this article online). Analysis of
somatic opiate withdrawal occurring 8 hr after the last
morphine injection revealed a genotype 3 opiate with-
drawal interaction effect for the jump (F2,49 = 4.18, p <
0.05), wet dog shake (F2,49 = 3.35, p < 0.05), and diarrhea
(F2,49 = 3.84, p < 0.05) signs. Opiate-withdrawn CRF1
/
mice made more jumps (p < 0.01; Figure 1A), wet dog
shakes (p < 0.005; Figure 1B), and diarrhea (p < 0.01;
Figure 1C) than all other groups. In contrast, opiate-with-
drawn wild-type and CRF1
+/ mice did not differ from con-
trol mice (Figures 1A, 1B, and 1C). Accordingly, during the
conditioning trials of an opiate withdrawal conditioned
place aversion experiment, opiate-withdrawn CRF1
/
mice displayed elevated levels of jumping and wet dog
shake, as compared to wild-type and CRF1
+/ mice (Con-
tarino and Papaleo, 2005). CRF1 receptor deficiency did
not affect other opiate withdrawal signs: overall, opiate-
withdrawn mice showed more paw tremors (F1,49 = 9.93,
p < 0.005), body stretches (F1,49 = 11.99, p < 0.005), chews
(F1,49 = 20.47, p < 0.0001), teeth chatters (F1,49 = 9.46, p <
0.005), palpebral ptoses (F1,49 = 4.17, p < 0.05), and body
weight loss (F1,49 = 21.10, p < 0.0001) than control mice
(Figure S2). Analysis of global opiate withdrawal (GOW)
scores also revealed a genotype 3 opiate withdrawal in-
teraction effect (F2,49 = 8.00, p < 0.001). Opiate-withdrawn
wild-type, CRF1
+/, and CRF1
/ mice displayed higher
GOW scores than control mice (p < 0.005). In addition,
opiate-withdrawn CRF1
/ mice showed higher GOW
scores than opiate-withdrawn wild-type and CRF1
+/
mice (p < 0.0005; Figure 1D). These results clearly indicate
a dramatic increase in major somatic signs of opiate with-
drawal in mice lacking functional levels of CRF1 receptors.
Long-Lasting Somatic Opiate
Withdrawal in CRF1
/ Mice
Another cohort of wild-type, CRF1
+/, and CRF1
/ mice
was used to assess the duration of somatic opiate with-
drawal. Monitoring of opiate withdrawal up to 152 hr after
the last morphine injection revealed a genotype 3 opiate
withdrawal 3 time interaction effect (F10,155 = 2.12, p <
0.05). CRF1
/ mice displayed elevated GOW scores at
least up to 104 hr after the last opiate injection (p < 0.05
versus all other groups). In net contrast, in wild-type and
CRF1
+/ mice somatic opiate withdrawal lasted less than
32 hr (Figure 1E). Thus, somatic opiate withdrawal was not
only more severe but also lasted much longer in CRF1
/
mice than in wild-type and CRF1
+/ mice. These results
also rule out a genotype-dependent time shift in somatic
opiate withdrawal: in all three genotypes, GOW scores.
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Somatic Opiate Withdrawal in CRF1
/
Mice
(A) Jumps, (B) wet dog shakes, (C) diarrhea, and
(D) global opiate withdrawal scores displayed
by control or opiate-withdrawn wild-type,
CRF1
+/, and CRF1
/ mice during a 30 min
test carried out 8 hr after the last vehicle or mor-
phine injection. n = 7–11/group. *p < 0.01, **p <
0.005 versus all other groups, ap < 0.005 versus
control mice, bp < 0.0005 versus opiate-with-
drawn wild-type and CRF1
+/ mice.
(E) Global opiate withdrawal scores of control
(white symbols) or opiate-withdrawn (black
symbols) wild-type, CRF1
+/, and CRF1
/
mice during daily 30 min tests carried out 32,
56, 80, 104, 128, and 152 hr after the last vehicle
or morphine injection. Values represent mean ±
SEM. n = 5–8/group. ***p < 0.0001, **p < 0.01,
*p < 0.05 versus all other groups at the same
time point.were maximal 8 hr after the last morphine injection (com-
pare Figures 1D and 1E).
Aberrant Hypothalamic CRF and Dynorphin
Expression in Opiate-Withdrawn CRF1
/ Mice
To search for brain changes underlying the increased so-
matic opiate withdrawal found in CRF1
/ mice, we exam-
ined CRF and dynorphin expression in the PVN (bregma
interval 0.94/1.22 mm). Analysis of PVN CRF expres-
sion in control and opiate-withdrawn wild-type and CRF1
receptor-deficientmice revealedan interestinggenotype3
opiate withdrawal interaction effect (F2,96 = 46.02, p <
0.0001). Opiate withdrawal increased CRF mRNA levels
in both wild-type and CRF1
+/ mice (p < 0.0005 versus
same genotype control mice). In net contrast, opiate with-
drawal markedly decreased PVN CRF expression in
CRF1
/ mice (p < 0.0005 versus control CRF1
/ mice;
Figure 2A). Thus, disruption of the CRF/CRF1 receptor
pathway severely impairs activation of PVN CRF circuitry
in response to the stress of opiate withdrawal. Exami-
nation of PVN dynorphin expression revealed a geno-
type 3 opiate withdrawal interaction effect (F2,96 = 9.05,Np < 0.0005). Opiate withdrawal did not affect dynorphin
expression either in wild-type or in CRF1
+/ mice. Drug-
naive control CRF1
/ mice showed higher dynorphin
mRNA levels than either control or opiate-withdrawn
wild-type and CRF1
+/ mice (p < 0.0005). Moreover, de-
spite the already elevated dynorphin mRNA levels, opiate
withdrawal further increased dynorphin expression in
CRF1
/ mice (p < 0.0005 versus control CRF1
/ mice;
Figures 2B and 2C).
These results clearly indicate that lack of functional
CRF1 receptors induces aberrant PVN CRF and dynorphin
responses to opiate withdrawal. HPA axis deficiencies as-
sociated with the genetic inactivation of the CRF/CRF1 re-
ceptor pathway might have contributed to the PVN CRF
and dynorphin alterations reported above. Drug-naive
adrenalectomized rats display increased hypothalamic
dynorphin levels (Almeida et al., 1992) as well as stress-
induced decreases in PVN CRF expression (Tanimura and
Watts, 1998). Furthermore, here we show that CRF1
+/
mice, which display neither basal nor stress-related ACTH
or corticosterone deficits (Contarino and Papaleo, 2005;
Timpl et al., 1998), displayed PVN CRF and dynorphineuron 53, 577–589, February 15, 2007 ª2007 Elsevier Inc. 579
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decided to assess the specific role for the impaired HPA
axis in the exacerbated somatic opiate withdrawal dis-
played by CRF1
/ mice.
Figure 2. Opiate-Withdrawn CRF1
/ Mice Display Aberrant
CRF and Dynorphin Expression in the Paraventricular
Nucleus of the Hypothalamus (PVN)
(A) CRF and (B) dynorphin mRNA levels in the PVN (bregma
interval: 0.94/1.22 mm) of control or opiate-withdrawn wild-type,
CRF1
+/, and CRF1
/ mice. Results are expressed as optical density.
Values represent mean ± SEM. n = 7–11 mice/group. *p < 0.005 versus
control and opiate-withdrawn wild-type and CRF1
+/ mice, **p <
0.0005 versus same genotype control mice, #p < 0.005, ##p < 0.001
versus control CRF1
/ mice.
(C) Negative images of Biomax-MR films of some representative brain
sections illustrating dynorphin mRNA levels in the PVN of control or
opiate-withdrawn wild-type, CRF1
+/, and CRF1
/ mice. Scale bar:
0.2 mm.580 Neuron 53, 577–589, February 15, 2007 ª2007 Elsevier Inc.Intake of Nonstressful Amounts of Corticosterone
Decreases the Severity of Somatic Opiate
Withdrawal in CRF1
/ Mice
To examine the contribution of impaired HPA axis func-
tions to somatic opiate withdrawal, CRF1
/ mice were
given free access to corticosterone in the home-cage
drinking water throughout intermittent opiate administra-
tion. Corticosterone intake restored nadir plasma cortico-
sterone levels (p < 0.05 versus corticosterone-untreated
CRF1
/ mice) but did not produce ‘‘stressful’’ plasma
corticosterone concentrations throughout the light-dark
cycle of the housing room (Figure 3). Eight hours after
the last opiate injection, corticosterone-untreated opiate-
withdrawn CRF1
/ mice showed higher levels of paw
tremor (p < 0.0005; Figure 4A), wet dog shake (p < 0.0005;
Figure 4B), diarrhea (p < 0.005; Figure 4C), and GOW
scores (p < 0.0005; Figure 4D) than control mice and opi-
ate-withdrawn wild-type mice. Treatment with corticoste-
rone effectively reduced paw tremors, wet dog shakes,
and GOW scores in CRF1
/ mice (p < 0.0005 versus cor-
ticosterone-untreated opiate-withdrawn CRF1
/ mice),
completely abolishing the difference between opiate-
withdrawn CRF1
/ and wild-type mice, but did not affect
the diarrhea sign (Figures 4A, 4B, 4C, and 4D). These re-
sults clearly indicate that deficient HPA axis activity
strongly contributes to aggravate the somatic outcome
of opiate withdrawal. At the end of the 30 min opiate
withdrawal test, corticosterone-treated and -untreated
CRF1
/ mice had similar plasma corticosterone levels
that were much lower than the stress-like levels displayed
by wild-type mice (p < 0.0005; Figure S3). The latter results
indicate that the beneficial effects of exogenous cortico-
sterone upon somatic components of opiate withdrawal
were not accompanied by a stress-like activity of the
HPA axis.
Corticosterone Restores PVN CRF Activation
in Opiate-Withdrawn CRF1
/ Mice
To examine if the decrease of somatic opiate withdrawal
by intake of nonstressful amounts of corticosterone was
associated to brain region-specific changes in gene ex-
pression, we examined CRF and dynorphin mRNA levels
in the PVN and the striatum of control and opiate-with-
drawn wild-type, corticosterone-untreated, or -treated
CRF1
/ mice. Analysis of PVN CRF expression (bregma
interval0.94/1.22 mm) revealed a group3 opiate with-
drawal interaction effect (F2,103 = 31.17, p < 0.0001). As in
our prior experiment reported above, opiate withdrawal
increased CRF expression in wild-type mice (p < 0.0005
versus control wild-type mice); in net contrast, opiate-
withdrawn corticosterone-untreated CRF1
/ mice dis-
played an aberrant decrease in CRF activity (p < 0.0005
versus corticosterone-untreated control CRF1
/ mice;
Figure 5A). Intake of corticosterone strongly reduced
PVN CRF expression in control CRF1
/ mice (p < 0.0005
versus control corticosterone-untreated CRF1
/ mice;
Figure 5A). Most interestingly, similar to the wild-type
mice, opiate-withdrawn corticosterone-treated CRF1
/
Neuron
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costerone-treated control CRF1
/ mice (p < 0.05; Figures
5A and 5B). Thus, in line with the behavioral results re-
ported above, CRF1
/ mice treated with corticosterone
showed ‘‘wild-type-like’’ patterns of PVN CRF expression
both under drug-naı¨ve and opiate withdrawal conditions.
Analysis of PVN dynorphin expression at the bregma
interval 0.94/1.22 mm revealed a group effect
Figure 3. Free Access to Corticosterone in the Home-Cage
DrinkingWater Restores Nadir Plasma Corticosterone Levels
in CRF1
/ Mice
Plasma corticosterone levels of wild-type, corticosterone-untreated
(CRF1
/), or -treated (CRF1
/ CORT) CRF1
/ mice, prior to inter-
mittent morphine administration. Corticosterone measures were taken
at the beginning of the light (nadir) or the dark (diurnal peak) phase
of the light-dark cycle of the colony room. Values represent mean ±
SEM. n = 6–8/group. *p < 0.05 versus wild-type and CRF1
/ CORT
‘‘nadir’’ levels, #p < 0.005 versus wild-type ‘‘nadir’’ levels (Student’s
t test).N(F2,99 = 24.87, p < 0.0001) and a group 3 opiate with-
drawal interaction effect (F2,99 = 6.38, p < 0.005). Cortico-
sterone lowered dynorphin expression in control and opi-
ate-withdrawn CRF1
/ mice (p < 0.05 versus same drug
treatment corticosterone-untreated CRF1
/ mice; Fig-
ure 6A). Similar to our previous results reported above,
opiate withdrawal did not affect PVN dynorphin expres-
sion in wild-type mice. Moreover, corticosterone-un-
treated control CRF1
/ mice showed higher dynorphin
mRNA levels than wild-type mice (p < 0.05; Figure 6A).
Opiate withdrawal increased PVN dynorphin expression
in either corticosterone-untreated or -treated CRF1
/
mice (p < 0.0005 versus control CRF1
/ mice; Figure 6A);
however, the latter displayed lower dynorphin mRNA
levels than the former group (p < 0.05; Figure 6A). Previous
studies have shown increased dynorphin gene expression
in the PVN of opiate-withdrawn rats (Lightman and Young,
1988). Thus, we examined PVN dynorphin mRNA levels in
another coronal slice (bregma interval 0.70/0.82 mm).
The latter analysis revealed a group 3 opiate withdrawal
interaction effect (F2,56 = 3.61, p < 0.05). At this coronal
level, both wild-type and corticosterone-untreated
CRF1
/ mice showed increased PVN dynorphin expres-
sion in response to opiate withdrawal (p < 0.05 versus
same genotype control mice; Figure 6B). In net contrast,
in CRF1
/ mice corticosterone completely abolished
the opiate withdrawal-induced dynorphin mRNA increase
(p < 0.01 versus opiate-withdrawn corticosterone-
untreated CRF1
/ mice; Figure 6B).
Thus, corticosterone intake decreased both basal and
opiate withdrawal-related PVN dynorphin expression in
CRF1
/ mice. Noteworthy, at both brain coronal sections
examined here, opiate-withdrawn corticosterone-treatedFigure 4. Treatment with Nonstressful
Amounts of Corticosterone Decreases
the Somatic Expression of Opiate With-
drawal in CRF1
/ Mice
(A) Paw tremors, (B) wet dog shakes, (C) diar-
rhea, and (D) global opiate withdrawal scores
displayed by control or opiate-withdrawn wild-
type, corticosterone-untreated (CRF1
/), or
-treated (CRF1
/ CORT) CRF1
/ mice during
a 30 min test carried out 8 hr after the last mor-
phine injection. Values represent mean ± SEM.
n = 7–11/group. *p < 0.005, **p < 0.0005 versus
control mice and opiate-withdrawn wild-type
mice, ##p < 0.0005 versus opiate-withdrawn
corticosterone-untreated CRF1
/ mice.euron 53, 577–589, February 15, 2007 ª2007 Elsevier Inc. 581
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/ mice showed lower PVN mRNA dynorphin levels
than opiate-withdrawn corticosterone-untreated CRF1
/
mice (Figures 6A and 6B).
Corticosterone Upregulates Striatal Dynorphin
Expression and Restores ‘‘Wild-Type-like’’
Responses to Opiate Withdrawal in CRF1
/ Mice
Examination of dynorphin expression in the striatum also
revealed a group 3 opiate withdrawal interaction effect
(F2,87 = 10.15, p < 0.0005). Overall, either corticoste-
rone-untreated or -treated CRF1
/ mice showed lower
dynorphin expression than wild-type mice (p < 0.0005;
Figure 7). In wild-type mice, opiate withdrawal decreased
the striatal expression of dynorphin (p < 0.0005 versus
Figure 5. Corticosterone Restores CRF Activation in the
Paraventricular Nucleus of the Hypothalamus (PVN) of
Opiate-Withdrawn CRF1
/ Mice
(A) CRF mRNA levels in the PVN (bregma interval: 0.94/1.22 mm)
of control or opiate-withdrawn wild-type, corticosterone-untreated
(CRF1
/), or -treated (CRF1
/ CORT) CRF1
/ mice. Results are ex-
pressed as optical density. Values represent mean ± SEM. n = 5–11
mice/group. *p < 0.05, **p < 0.0005 versus same genotype and corti-
costerone treatment control mice, ##p < 0.005 versus corticoste-
rone-untreated control CRF1
/ mice.
(B) Negative images of Biomax-MR films of some representative brain
sections illustrating CRF mRNA levels in the PVN of control or opiate-
withdrawn wild-type, corticosterone-untreated (CRF1
/), or -treated
(CRF1
/ CORT) CRF1
/ mice. Scale bar: 0.2 mm.582 Neuron 53, 577–589, February 15, 2007 ª2007 Elsevier Incontrol wild-type mice; Figure 7). The latter results agree
with previous studies showing decreased dynorphin ex-
pression in rats withdrawn from chronic exposure to
morphine (Georges et al., 1999; Tjon et al., 1997). In net
contrast, although not significantly, opiate withdrawal
increased striatal dynorphin mRNA levels in corticoste-
rone-untreated CRF1
/ mice (p = 0.070 versus control
corticosterone-untreated CRF1
/ mice). Corticosterone
intake raised striatal dynorphin expression in control
CRF1
/ mice (p < 0.01 versus control corticosterone-
untreated CRF1
/ mice; Figure 7). Most importantly, con-
trary to the corticosterone-untreated CRF1
/ mice, opi-
ate withdrawal decreased striatal dynorphin expression
in corticosterone-treated CRF1
/ mice (p < 0.05 versus
control corticosterone-treated CRF1
/ mice; Figure 7).
Thus, similar to the wild-type mice, corticosterone-treated
opiate-withdrawn CRF1
/ mice displayed decreased,
Figure 6. Corticosterone Decreases Dynorphin Expression in
the Paraventricular Nucleus of the Hypothalamus (PVN) of
Opiate-Withdrawn CRF1
/ Mice
PVN dynorphin mRNA levels at bregma intervals: (A)0.94/1.22 mm
and (B) 0.70/0.82 mm, of control or opiate-withdrawn wild-type,
corticosterone-untreated (CRF1
/), or -treated (CRF1
/ CORT)
CRF1
/ mice. Results are expressed as optical density. Values repre-
sent mean ± SEM. n = 7–11 and 3–7 mice/group for (A) and (B), respec-
tively. *p < 0.05, **p < 0.0005 versus same genotype and corticoste-
rone treatment control mice, #p < 0.05 versus same drug treatment
corticosterone-untreated CRF1
/ mice.c.
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striatum.
Pharmacological Disruption of the CRF/CRF1
Receptor Pathway Exacerbates the Somatic
Signs of Opiate Withdrawal
To assess the HPA axis-independent role for the CRF/
CRF1 receptor pathway in somatic opiate withdrawal,
we used the CRF1 receptor-preferring antagonist antalar-
min. Following peripheral administration, antalarmin read-
ily crosses the blood-brain barrier and does not affect
basal or stress-related activity of the HPA axis (Jutkiewicz
et al., 2005; Wong et al., 1999). Antalarmin-treated opiate-
withdrawn wild-type and CRF1
+/ mice showed higher
levels of paw tremor (F1,30 = 17.84, p < 0.0005; Figure 8A),
chew (F1,30 = 29.21, p < 0.0001; Figure 8B), body stretch
(F1,30 = 5.35, p < 0.05; Figure 8C), and GOW scores
(F1,30 = 22.36, p < 0.0001; Figure 8D) than vehicle-treated
opiate-withdrawn mice. Antalarmin did not affect the
expression of other opiate withdrawal signs (data not
shown). At the end of the 30 min opiate withdrawal test,
antalarmin- and vehicle-treated wild-type mice displayed
similar plasma corticosterone levels (Figure S4), indicating
that the CRF1 receptor antagonist did not affect HPA axis
responses to the stress of opiate withdrawal. These re-
sults clearly indicate that pharmacological disruption of
the brain extrahypothalamic CRF/CRF1 receptor pathway
exacerbates the somatic expression of opiate withdrawal.
DISCUSSION
This report demonstrates, by both a genetic and a pharma-
cological approach, that disruption of the CRF/CRF1 re-
ceptor pathway and related HPA axis activity dramatically
Figure 7. Corticosterone Upregulates Striatal Dynorphin
Expression and Restores ‘‘Wild-Type-like’’ Responses to
Opiate Withdrawal in CRF1
/ Mice
Dynorphin mRNA levels in the striatum of control or opiate-withdrawn
wild-type, corticosterone-untreated (CRF1
/), or -treated (CRF1
/
CORT) CRF1
/mice. Results are expressed as optical density. Values
represent mean ± SEM. n = 6–11 mice/group. *p < 0.05, **p < 0.0005
versus control mice, #p < 0.01, ##p < 0.0005 versus corticosterone-
untreated control CRF1
/ mice.Nincreases the somatic expression of opiate withdrawal. In
particular, CRF1
/ mice showed increased levels of so-
matic opiate withdrawal as well as aberrant CRF and dy-
norphin gene expression in the PVN and striatum brain
regions. Intake of nonstressful amounts of corticosterone
prior to and throughout morphine exposure reliably re-
duced the exacerbated somatic reactions of CRF1
/
mice to opiate withdrawal. Also, corticosterone intake
restored ‘‘wild-type-like’’ patterns of opiate withdrawal-
induced PVN CRF and striatal dynorphin gene expression
in CRF1
/ mice. The use of antalarmin also allowed us to
unravel a HPA axis-independent modulatory (inhibitory)
role for brain CRF/CRF1 receptor circuitry upon the so-
matic expression of opiate withdrawal.
To mimic the clinical setting, in the present study mice
were treated with intermittent escalating morphine doses
and opiate withdrawal-related alterations assessed follow-
ing ‘‘spontaneous’’ drug clearance from the body. Using
such a clinically oriented paradigm, we found that during
early opiate withdrawal, i.e., 8 hr after the last morphine in-
jection, CRF1
/mice displayed elevated levels of somatic
malaise, as compared to wild-type and CRF1
+/ mice. So-
matic opiate withdrawal signs were not only more severe
but also lasted much longer in CRF1
/ mice than in
wild-type and CRF1
+/ mice. In CRF1
/ mice, reliable
signs of opiate withdrawal could be detected at least up
to 104 hr after the last opiate injection; in net contrast, in
wild-type and CRF1
+/ mice somatic opiate withdrawal
lasted less than 32 hr. In the present study, like in the clin-
ical setting, between successive morphine injections the
mice experienced the malaise of opiate withdrawal. The
twice-daily partial opiate withdrawal that accompanied
our drug regimen may have served as a severe chronic
stressor. Accordingly, 12 hr after morphine dosing, rats
treated with a morphine regimen similar to that used here
displayed stress-like alterations in brain, HPA axis, and
metabolic functions (Houshyar et al., 2004). Stressors trig-
ger endocrine and behavioral adaptive responses that are
aimed at reinstating homeostasis. The brain extrahypotha-
lamic CRF/CRF1 receptor pathway and the HPA axis are
major components of the stress-responsive system (de
Kloet et al., 2005). CRF1
/ mice display consistent alter-
ations in stress-related affective-like behaviors, a pro-
nounced atrophy of the corticosterone-producing zona
fasciculata of the adrenal gland cortex and deficient
ACTH and corticosterone responses to stressors (Contar-
ino et al., 1999; Contarino and Papaleo, 2005; Smith et al.,
1998; Timpl et al., 1998). Here, we provide initial evidence
that genetic disruption of the HPA axis and brain extrahy-
pothalamic CRF/CRF1 receptor circuitry increased both
the severity and the duration of somatic signs of opiate
withdrawal. These findings clearly indicate that failure to
adequately activate stress-responsive CRF/CRF1 recep-
tor circuitry may lead to exaggerated somatic reactions
to opiate withdrawal.
The present gene expression studies add novel evi-
dence in favor of a disrupted stress-responsive system
in CRF1
/ mice. Here, we examined CRF and dynorphineuron 53, 577–589, February 15, 2007 ª2007 Elsevier Inc. 583
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CRF1 Disruption Enhances Somatic Opiate WithdrawalFigure 8. Pharmacological Disruption of
the Extrahypothalamic Brain CRF/CRF1
Receptor Pathway Exacerbates the So-
matic Expression of Opiate Withdrawal
(A) Paw tremors, (B) chews, (C) body stretches,
and (D) global opiate withdrawal scores
displayed by vehicle- or antalarmin-treated
opiate-withdrawn wild-type and CRF1
+/ mice
during a 30 min test carried out 8 hr after the
last morphine injection. Values represent
mean ± SEM. n = 8–9/group. *p < 0.05, **; p <
0.0005, ***p < 0.0001 versus opiate-withdrawn
vehicle-treated mice.expression in the PVN and the striatum, brain regions
implicated in behavioral, endocrine, and autonomic re-
sponses to stress (Koob and Heinrichs, 1999; Reyes
et al., 2005). Activation of PVN CRF circuitry is pivotal
for coordinating HPA axis and behavioral-adaptive re-
sponses to severe stressors. Accordingly, here we show
that both wild-type and CRF1
+/ mice responded to the
stress of opiate withdrawal with an increase in PVN CRF
expression. In net contrast, in CRF1
/ mice opiate with-
drawal induced an aberrant decrease in PVN CRF activity,
indicating profound impairments in key substrates under-
lying adaptive responses to drug withdrawal-related
stressful conditions. Circulating glucocorticoid hormones
regulate basal and stress-related activity of PVN CRF cir-
cuitry (Tanimura and Watts, 1998). We hypothesized that
the glucocorticoid deficiency associated with the genetic
disruption of the CRF/CRF1 receptor pathway contributed
to deregulate both basal and opiate withdrawal-related
PVN CRF expression, thus exaggerating the somatic reac-
tions to opiate withdrawal. To address this question,
CRF1
/ mice were given free access to corticosterone
in the home-cage drinking water prior to and throughout
intermittent morphine treatment. We found that intake
of nonstressful amounts of corticosterone effectively
reduced the exaggerated somatic reactions of CRF1
/
mice to opiate withdrawal. In particular, corticosterone in-
take clearly decreased the expression of paw tremors and
wet dog shakes in opiate-withdrawn CRF1
/ mice, com-
pletely eliminating the difference with the wild-type mice.
Corticosterone also markedly downregulated PVN CRF
expression in drug-naive CRF1
/ mice, as compared
to corticosterone-untreated drug-naive CRF1
/ mice.
Most interestingly, unlike the aberrant decrease in PVN584 Neuron 53, 577–589, February 15, 2007 ª2007 Elsevier IncCRF expression observed in corticosterone-untreated
opiate-withdrawn CRF1
/ mice, intake of nonstressful
amounts of corticosterone fully restored ‘‘wild-type-like’’
patterns of PVN CRF activation in opiate-withdrawn
CRF1
/ mice. Most likely, the ‘‘beneficial’’ behavioral
effects of exogenous corticosterone observed here were
due to enduring changes in the HPA system, which were
taking place throughout the entire period of free access
to the glucocorticoid hormone in the drinking water. Nota-
bly, changes in the activity of the type 2 corticosteroid re-
ceptor, glucocorticoid receptor (GR), may have underlain
the corticosterone effects reported here. We have prelim-
inary data indicating increased GR nuclear translocation
in the hypothalamus and hippocampus of CRF1
/ mice,
which is normalized by the same corticosterone treatment
used here (P.K., A.C., F.P., and P. Piazza, unpublished
data). In support of a role for the GR in the stress response,
studies have shown increased behavioral reactivity to
stressors in mice with PVN and hippocampal GR overex-
pression (Wei et al., 2004). Activation of PVN GR by gluco-
corticoid hormones is thought to downregulate the ex-
pression of CRF in this brain region (Sawchenko, 1987).
Accordingly, here we clearly show that treatment with
corticosterone sharply decreased PVN CRF expression
in CRF1
/ mice. Furthermore, we demonstrated that
treatment with corticosterone restored ‘‘wild-type-like’’
patterns of PVN CRF activation in response to opiate
withdrawal. Thus, despite that further work is needed to
elucidate the functional outcome of upregulated GR
translocation in the hypothalamus and hippocampus of
CRF1
/ mice, our studies clearly show that intake of non-
stressful amounts of corticosterone ‘‘normalize’’ PVN GR
nuclear translocation as well as PVN CRF expression.
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/ mice to opiate with-
drawal. Overall, our results support a major role for the
HPA system in brain and somatic alterations induced by
opiate withdrawal.
Our studies also revealed elevated PVN dynorphin ex-
pression in drug-naive corticosterone-untreated CRF1
/
mice. Upregulated PVN dynorphin activity might indicate a
chronic ‘‘stress-like’’ state. Stressors increase dynorphin
immunoreactivity in limbic brain regions (Shirayama
et al., 2004) and in the hypothalamus (Nabeshima et al.,
1992), and pharmacological as well as genetic disruption
of dynorphin activity attenuate the behavioral effects of
stress exposure (McLaughlin et al., 2003; Shirayama
et al., 2004). We also found that, despite the elevated
‘‘basal’’ dynorphin mRNA levels, opiate withdrawal further
increased PVN dynorphin expression in corticosterone-
untreated CRF1
/ mice. Corticosterone intake de-
creased both basal and opiate withdrawal-related PVN
dynorphin expression in CRF1
/ mice. In particular, at
both coronal slices examined in the present study, opi-
ate-withdrawn corticosterone-treated CRF1
/ mice
showed lower PVN mRNA dynorphin levels than opiate-
withdrawn corticosterone-untreated CRF1
/ mice. PVN
dynorphin neurons project to autonomic nervous system
centers that are activated during opiate withdrawal, such
as the nucleus of the tractus solitarius, the parabrachial
nucleus, and the spinal cord (Fallon and Ciofi, 1990; Stor-
netta et al., 1993). Thus, we cannot exclude a role for
the corticosterone-linked PVN dynorphin expression in
the decreased somatic opiate withdrawal displayed by
corticosterone-treated CRF1
/ mice. However, despite
the similar somatic opiate withdrawal profiles, the level
of PVN dynorphin expression found in corticosterone-
treated CRF1
/ mice differed from that observed in opi-
ate-withdrawn wild-type mice. Thus, further studies might
be needed to better understand the implication of the
glucocorticoid-dependent PVN dynorphin activity in the
exacerbated somatic reactions of CRF1
/ mice to opiate
withdrawal.
The present molecular biology studies also showed that
drug-naive corticosterone-untreated CRF1
/ mice dis-
played a marked decrease in striatal dynorphin gene ex-
pression, as compared to wild-type mice. The decreased
dynorphin expression found in the striatum of CRF1
/
mice may have function to exacerbate the somatic conse-
quences of opiate exposure and withdrawal. Accordingly,
mice overexpressing DFosB in dynorphin neurons of the
striatum and the nucleus accumbens displayed de-
creased dynorphin mRNA levels in the striatum as well
as increased somatic signs of opiate withdrawal (McClung
et al., 2004; Zachariou et al., 2006). Accordingly, studies
have shown that withdrawal from an intermittent morphine
treatment similar to that used here increased DFosB im-
munoreactivity in the striatum (Muller and Unterwald,
2005). Thus, since intake of corticosterone reduced the
severity of somatic opiate withdrawal, we examined stria-
tal dynorphin expression in drug-naive or opiate-with-
drawn wild-type, corticosterone-untreated or -treatedNCRF1
/ mice. Treatment with corticosterone increased
the striatal expression of dynorphin in drug-naive CRF1
/
mice. The latter results agree with prior studies showing
decreased striatal dynorphin expression in adrenalecto-
mized rats, which is upregulated by exogenous cortico-
sterone (Lucas et al., 1998). Moreover, in net contrast
with the aberrant increase observed in corticosterone-
untreated CRF1
/ mice, opiate withdrawal decreased
the expression of striatal dynorphin in corticosterone-
treated CRF1
/ mice, a pattern similar to that observed
in wild-type mice. Overall, our results suggest that upregu-
lated dynorphin expression induced by exogenous corti-
costerone may have ‘‘protected’’ the CRF1
/ mice from
the negative consequences of opiate exposure and with-
drawal. Together with recent studies (Zachariou et al.,
2006), the present findings add further support to a previ-
ously unsuspected role for dysregulated striatal dynorphin
activity in somatic components of the opiate withdrawal
syndrome.
The use of antalarmin allowed us to examine the HPA
axis-independent role for the CRF/CRF1 receptor pathway
in opiate withdrawal. Antalarmin is a highly lipophilic CRF1
receptor-preferring antagonist that, following peripheral
administration, readily crosses the blood-brain barrier and
does not affect HPA axis responses to stressors. Both
acute and chronic antalarmin failed to blunt ACTH and
corticosterone responses to either an immobilization or a
swim stress (Jutkiewicz et al., 2005; Wong et al., 1999).
Accordingly, in the present study antalarmin did not re-
duce HPA axis responses to the stress of opiate with-
drawal. In contrast, antalarmin reliably increased the so-
matic expression of opiate withdrawal in both wild-type
and CRF1
+/ mice. Thus, in spite of a preserved stress-
like HPA axis activity, disruption of the extrahypothalamic
brain CRF/CRF1 receptor pathway exacerbated the so-
matic expression of opiate withdrawal. These results
unravel an inhibitory role for central CRF/CRF1 receptor
circuitry upon somatic features of opiate withdrawal,
which may be independent of the HPA axis. Our findings
contrast with prior studies showing reduction of somatic
opiate withdrawal by other CRF1 receptor-preferring
antagonists (Iredale et al., 2000; Lu et al., 2000). However,
the latter studies employed opioid-receptor antagonist-
precipitated opiate withdrawal procedures whereas
herein we used a more clinically relevant spontaneous opi-
ate withdrawal paradigm. Major behavioral and molecular
differences between spontaneous and opioid-receptor
antagonist-precipitated opiate withdrawal procedures
(Fukunaga and Kishioka, 2000; Houshyar et al., 2004; Lin-
seman, 1977) make it difficult to compare the present with
prior studies.
We have recently reported that either CRF1
+/ or
CRF1
/ mice lack the affective-like signs of opiate with-
drawal (Contarino and Papaleo, 2005). Here, we clearly
show that CRF1
/ mice display increased somatic reac-
tions to opiate withdrawal, which are abolished by treat-
ment with corticosterone. Also, in response to opiate with-
drawal, neither CRF1
+/ nor CRF1
/ mice displayedeuron 53, 577–589, February 15, 2007 ª2007 Elsevier Inc. 585
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cleus accumbens (Contarino and Papaleo, 2005), a brain
region underlying negatively valenced affective states
(Nestler, 2001). Moreover, here we show that opiate-with-
drawn CRF1
/ mice displayed aberrant CRF and dynor-
phin expression in the PVN and the striatum, which were
reversed by intake of nonstressful amounts of corticoste-
rone. Thus, the increased somatic opiate withdrawal dis-
played by CRF1
/mice largely depended on the impaired
HPA axis associated with the genetic inactivation of the
CRF/CRF1 receptor pathway. In contrast, the HPA axis
may be less involved in the affective components of
the opiate withdrawal syndrome since neither CRF1
+/
nor CRF1
/ mice, which greatly differ in both basal and
stress-related HPA axis activity (Contarino and Papaleo,
2005; Timpl et al., 1998), showed the negative affective-
like states of opiate withdrawal (Contarino and Papaleo,
2005). Human as well as rodent studies indicate that so-
matic and affective components of the opiate withdrawal
syndrome are dissociable at a number of levels of analysis
(Mucha, 1987; Schulteis and Koob, 1996). Our findings of
a clear-cut dissociation of affective-like and somatic signs
of opiate withdrawal in CRF1 receptor-deficient mice pro-
vide novel and robust evidence in support of the latter no-
tion. The opposite changes in somatic and affective-like
signs of opiate withdrawal found in CRF1 receptor-defi-
cient mice point to this genetically engineered mouse
model as a unique tool to determine the relative contribu-
tion of opiate withdrawal-induced somatic malaise and
negative affective states to opiate dependence.
In conclusion, here we show that disruption of major
components of the stress-responsive system exacer-
bates the somatic expression of opiate withdrawal and
induces brain and endocrine changes suggestive of in-
creased somatic vulnerability to the stress of opiate with-
drawal. The vast majority of the studies carried out to date
indicate that acute withdrawal from essentially all drugs of
abuse is associated with increased HPA axis and brain ex-
trahypothalamic CRF activity, which are thought to under-
lie the negative consequences of drug withdrawal (Koob
and Le Moal, 2001; Kreek and Koob, 1998). The findings
of the present study demonstrate that, like hyperactive
stress systems, severe deficiencies in major components
of the stress-responsive system may worsen the somatic
reactions to drug withdrawal.
EXPERIMENTAL PROCEDURES
Subjects
Group-housed, littermate, female mice that were wild-type, CRF1-
receptor heterozygous (CRF1
+/) or homozygous (CRF1
/) were used
throughout (Smith et al., 1998). Mice were 4–8 months old and derived
from mating CRF1
+/ breeders. Wild-type, CRF1
+/, and CRF1
/ off-
spring of CRF1
+/ breeders were identified by PCR analysis of tail DNA.
The mice were housed in a colony room maintained at 22C on a 12 hr
light/dark cycle (lights on from 8 a.m. until 8 p.m.). Food and water
were available ad libitum. Mice were handled on alternate days during
the week preceding drug administration. All studies were conducted in
accordance with the Guide for the Care and Use of Laboratory Animals586 Neuron 53, 577–589, February 15, 2007 ª2007 Elsevier Incof the National Institutes of Health and were approved by the local
Animal Care and Use Committee.
Somatic Opiate Withdrawal
During 6 consecutive days, wild-type, CRF1
+/, and CRF1
/ mice
were treated every 12 hr (8–10 a.m.; 8–10 p.m.) with vehicle or increas-
ing doses of morphine according to the following protocol: day 1, 20
mg/kg; day 2, 40 mg/kg; day 3, 60 mg/kg; day 4, 80 mg/kg; day 5,
100 mg/kg; day 6, 100 mg/kg, only one injection in the morning. Eight
hours after last injection, mice were individually placed into transparent
Plexiglas cylinders (diameter, 23 cm; height, 50 cm) and observed for
the occurrence of opiate withdrawal signs during the following 30 min.
We have observed that, in mice, somatic expression of spontaneous
opiate withdrawal is maximal 8 hr after the last morphine injection (Pa-
paleo and Contarino, 2006). Jump, paw tremor, wet dog shake, and
body stretch were counted as number of events occurring during the
total test time (graded signs); chew, teeth chatter, diarrhea, and palpe-
bral ptosis were counted as number of 5 min intervals in which it oc-
curred (checked signs, maximal score = 6). BWs were recorded imme-
diately before and after the 30 min test session and percentage of BW
changes calculated. For each mouse, a global opiate withdrawal score
was also calculated by summing each sign value. For this purpose, one
point was assigned to every three jumps and five paw tremors, respec-
tively. To examine the duration of somatic opiate withdrawal, another
cohort of wild-type, CRF1
+/, and CRF1
/ mice was treated with
vehicle or morphine as described above and then tested for somatic
opiate withdrawal 32, 56, 80, 104, 128, and 152 hr following the last
injection.
Pharmacological Antagonism of the CRF/CRF1
Receptor Pathway
Wild-type and CRF1
+/ mice were treated with morphine as described
above. Eight hours after the last drug injection, the mice were tested for
the occurrence of somatic opiate withdrawal signs. Forty-five minutes
prior to the test, within each genotype mice were treated with the
appropriate vehicle or antalarmin (20 mg/kg, i.p.).
CRF and Dynorphin In Situ Hybridization Histochemistry
At the end of the 30 min somatic opiate withdrawal test, the mice were
taken into another room, their brains rapidly removed, frozen in isopen-
tane (40C), and then stored at 80C. Brains were cut in coronal
sections (12 mm) using a cryostat and thaw mounted onto gelatin-
covered slides to be processed for in situ hybridization. The in situ hy-
bridization procedure was performed with oligonucleotide probes
designed to recognize the dynorphin (Jaber et al., 1995) or the CRF
(complementary to rat CRF; bases 731–778) mRNA. Oligonucleotide
probes were labeled by tailing with [35S]dATP (Perkin Elmer, SAS,
France) using terminal deoxynucleotide transferase (Promega, Madi-
son, WI). The specific activity of the oligonucleotide probes was 45
3 107 cpm/mg and 65 3 107 cpm/mg for dynorphin and CRF, respec-
tively. After labeling, the probes were precipitated in absolute ethanol
and 5 M sodium chloride, dried, and resuspended at the concentration
of 4.25 pg/ml in the hybridization buffer (50% deionized formamide,
20% dextran sulfate, 20% 203 SSC, sodium chloride-sodium citrate,
500 mg/ml denatured salmon sperm DNA, 1% Denhardt, 5% sarcosyl,
240 mg/ml tRNA, 2.4 mg/ml NaH2PO4). The sections were fixed with
4% paraformaldehyde in phosphate buffer 0.1 M (pH 7.2) for 5 min
at room temperature, rinsed twice for 30 min with 43 SSC (2% Den-
hardt), acetylated into 43 SSC (0.25% acetic anhydride, 1.33% trie-
thanolamine [pH 8]) for 10 min at room temperature and then dehy-
drated in graded alcohol. The slides were then incubated horizontally
overnight at 40C with the hybridization solution containing the labeled
probe (40 ml/slide). At the end of the incubation, slides were washed in
decreasing concentrations of SSC and dehydrated in ethanol. Sec-
tions were exposed at room temperature to Biomax-MR film (Kodak,
Polylabo, Strasbourg, France) over 15–20 days. The Biomax-MR films
were quantified using a GS-800 scanner (in transmission mode) and.
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les, CA). The optical density (OD) of each pixel was measured with ref-
erence to built-in OD standards. A region defining the paraventricular
nucleus of the hypothalamus (PVN) or the striatum was drawn on the
Biomax-MR film and the OD of each pixel was measured and multi-
plied by the region surface (OD*mm2). Values obtained were then
corrected by substracting film background ‘‘noise’’ and multiplied by
103. For each mouse, two coronal levels of the PVN (bregma in-
terval 0.70/0.82 or 0.94/1.22 mm) as well as the striatum
(bregma interval 0.70/1.22 mm) of both cerebral hemispheres
were quantified (Paxinos and Franklin, 2001).
Treatment with Corticosterone and Plasma
Corticosterone Assay
Wild-type and CRF1
/ mice were injected with vehicle or morphine
and tested for somatic opiate withdrawal 8 hr after the last injection,
as described above. Starting 5 days prior to the beginning of and
throughout intermittent vehicle or morphine administration, 15 out of
36 CRF1
/ mice were treated with corticosterone. Briefly, corticoste-
rone (Sigma-Aldrich, St. Louis, MO) was dissolved in 95% ethanol and
then added to the home-cage drinking water (5 mg/ml; final concentra-
tion of ethanol was 0.2%). Wild-type and corticosterone-untreated
CRF1
/ mice had the same ethanol concentration in the drinking wa-
ter. On the day prior to the beginning of vehicle or morphine adminis-
tration, two tail blood samples were collected from each mouse at
9 a.m. and 9 p.m. Immediately after the 30 min opiate withdrawal
test, blood samples were collected from the trunk and brains rapidly
removed for later in situ hybridization studies. Plasma samples were
stored at 20C until corticosterone assay. Plasma corticosterone
levels were quantified by radioimmunoassay (RIA) using a specific
corticosterone antibody (ICN Pharmaceuticals). The intra- and interas-
say coefficients of variation were approximately 3.5% and 8%,
respectively.
Drugs
Morphine HCl (SALARS, Como, Italy; 20–100 mg/kg, i.p.) was dis-
solved in physiological saline. Antalarmin (20 mg/kg, i.p.) was sus-
pended in carboxymethylcellulose (0.5%) and dissolved in physiolog-
ical saline (pH of diluent was 4.1–4.5). The volume of the injections was
10 ml/kg throughout. Within each experiment, control mice were
injected with the appropriate vehicle.
Statistical Analysis
The two-way analysis of variance (ANOVA) with genotype (wild-type,
CRF1
+/ or CRF1
/ mice) and treatment (control or opiate-withdrawn)
as independent variables was used to examine somatic opiate with-
drawal signs observed 8 hr after the last vehicle or morphine injection,
and CRF and dynorphin mRNA levels of the PVN. The three-way
ANOVA with genotype and treatment as between subjects factors
and time as a within-subject repeated measure was used to analyze
percentage of BW loss during intermittent morphine treatment, and
GOW scores recorded 32, 56, 80, 104, 128, and 152 hr after the last
vehicle or morphine injection. The two-way ANOVA with genotype
(wild-type or CRF1
+/ mice) and treatment (vehicle or antalarmin) as
independent variables was used to analyze somatic opiate withdrawal
signs of the antalarmin study. The two-way ANOVA with group (wild-
type, corticosterone-untreated, or -treated CRF1
/ mice) and treat-
ment (control or opiate-withdrawn) as independent variables was
used to examine somatic opiate withdrawal signs as well as PVN
and the striatal CRF and dynorphin mRNA levels of the corticosterone
study. The one-way ANOVA was used to examine baseline and opiate
withdrawal-related plasma corticosterone levels of wild-type, cortico-
sterone-untreated, or -treated CRF1
/ mice. The Student-Newman-
Keuls post-hoc test was used for individual group comparisons. The
accepted value for significance was p < 0.05.NSupplemental Data
The Supplemental Data for this article can be found online at http://
www.neuron.org/cgi/content/full/53/4/577/DC1/.
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